The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019
Hye-Na Kang,Robin Thorpe,Ivana Knezevic,Survey participants from 19 countries,Carolina Damas Rocha Zarate Blades,Mary Casas Levano,Jing Yin Chew,Mumbi Bernice Chilufya,Parichard Chirachanakul,Hui Ming Chua,Ali Vasheghani Farahani,Mariam Raouf Wefky Ghobrial,Suna Habahbeh,Hugo Hamel,Gi Hyun Kim,Violeta Perez Rodriguez,Desi Eka Putri,Jacqueline Rodgers,Maria Savkina,Oleh Semeniuk,Shraddha Srivastava,Meenu Wadhwa,Teruhide Yamaguchi
DOI: https://doi.org/10.1016/j.biologicals.2020.02.005
IF: 1.76
Biologicals
Abstract:The World Health Assembly in 2014 adopted a resolution that mandates both Member States and the WHO Secretariat to facilitate access to biotherapeutic products in a way that ensures their quality, safety and efficacy. The availability of biosimilars is expected to increase access to biotherapeutic products by providing more treatment options triggering competition which would lead to a consistent reduction in the average price of treatment. Since the WHO guidelines for regulatory evaluation of biosimilars were issued in 2009, WHO has provided immense effort towards harmonizing the terminology and the regulatory framework for biosimilars globally. This article describes the progress made and the regulatory landscape changes for biosimilars in 21 countries during the past ten years. Based on the information from regulators and from publicly available data, the following has been identified: 1) WHO guidelines have contributed to setting the regulatory framework for biosimilars in countries and increasing regulatory convergence at global level; 2) terminology used for biosimilars is more consistent than in the past; 3) biosimilars are now approved in all participating countries; and 4) the dominant product class for candidate biosimilars under development is monoclonal antibodies.